Investors

Euronext Amsterdam: DSFIR

We're dsm-firmenich - innovators in nutrition, health, and beauty

As a high-value consumer ingredients leader, we’re making rapid progress on our strategic journey to resilient growth

Latest results - Q3 2026

Q3 2026 highlights

  • Good like-for-like (LFL) sales growth of 5% in the quarter, consistent with year-to-date performance
  • Further sequential step-up in Adjusted EBITDA margin to 20.4% in the quarter
  • 2026-2028 action plan aimed at accelerating financial performance, fully on track
  • FY 2026 Outlook: LFL sales growth increased to around 5% (previously 2-4%)

Why invest in dsm-firmenich

dsm-firmenich are innovators in nutrition, health, and beauty, bringing progress to life through solving the tension between what people individually want (the desirable), what we collectively need (the essential) and what the planet demands (the sustainable).

We are strategically placed to capitalise on the positive long-term mega trend of holistic well-being which is fuelling above-market growth opportunities in our three, synergistic BUs operating in nutrition, health, and beauty creating and innovating in an integrated way.

Demand for fragrances and beauty products has surged, with scent being a key purchase driver

Consumers are prioritizing healthy nutrition 

The share of spend on preventative health is increasing year on year 

Our purpose

We have deep roots and a bright future, with unrivaled expertise that drives positive impact in everything we do. Our purpose is to bring progress to life – creating a world of potential for customers, communities, consumers, and investors.

Latest news

  • dsm-firmenich reports Q3 2026 trading update

    4 November 2026

    dsm-firmenich reports Q3 2026 trading update

  • dsm-firmenich shareholders elect Richard Ridinger as Chairman of the Board of Directors

    19 October 2026

    dsm-firmenich shareholders elect Richard Ridinger as Chairman of the Board of Directors

  • dsm-firmenich Board of Directors proposes Richard Ridinger as new Chairman following Thomas Leysen’s decision to retire

    18 August 2026

    dsm-firmenich Board of Directors proposes Richard Ridinger as new Chairman following Thomas Leysen’s decision to retire

Contact Investor Relations

Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.

Explore more
  • dsm-firmenich at a glance

    Who we are. What we do. Where we’re going.

  • Analyst coverage & consensus

    The sell-side analysts covering dsm-firmenich and latest Vara consensus figures.

  • Financial calendar

    A handy overview of the key dates in our financial calendar.

Stay up to date

Be the first to know about key news as we continue shaping the future and bringing progress to life.